- Inspira Technologies (NASDAQ:IINN) has announced a strategic shift to accelerate the commercialization of its U.S. FDA cleared INSPIRA™ ART100 system, while maintaining the development and regulatory pathways of its portfolio of products.
- This development follows the initial clinical implementation of
Inspira stock soars on initiating global commercial rollout of ART100 system
16 hours ago
1
Related
Govt eyes major revamp of accident compensation rules; trust...
9 minutes ago
0
Ulta Beauty in charts: Sales growth picks up Y/Y, records 6 ...
17 minutes ago
0
Bessent: U.S.-China trade talks 'a bit' stalled, Trump and X...
26 minutes ago
0
Vodafone Idea Q4 FY25 Preview: Loss likely to widen sequenti...
26 minutes ago
0
New World seeks more banks to join up to $2 billion loan - r...
37 minutes ago
0
Spain's inflation drops 1.9% Y/Y in May
48 minutes ago
0
West Point Gold prices C$7 million private placement
1 hour ago
0
TAT Technologies prices offering at $26 per share
1 hour ago
0
Germany's retail sales rise 2.3% Y/Y in April
1 hour ago
0
Superbuzz announces CFO transition
1 hour ago
0
Popular
English (US) · © FBT Company 2025. All rights are reserved